RT Journal Article
SR Electronic
T1 Autologous hematopoietic stem cell transplantation in multiple sclerosis
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 2115
OP 2122
DO 10.1212/WNL.0000000000003987
VO 88
IS 22
A1 Sormani, Maria Pia
A1 Muraro, Paolo A.
A1 Schiavetti, Irene
A1 Signori, Alessio
A1 Laroni, Alice
A1 Saccardi, Riccardo
A1 Mancardi, Gian Luigi
YR 2017
UL http://n.neurology.org/content/88/22/2115.abstract
AB Objective: To summarize the evidence on immunoablative therapy followed by autologous hematopoietic stem cell transplantation (aHSCT) to manage severe and treatment-refractory multiple sclerosis (MS).Methods: We collected all the published studies of aHSCT in any form of MS from 1995 to 2016, carefully excluding reports that were updated in subsequent studies. Endpoints were transplant-related mortality (TRM), rate of disease progression, and no evidence of disease activity (NEDA) status. A weighted metaregression based on a Poisson model was run, assessing whether there were study-specific characteristics with an effect on TRM and progression.Results: Fifteen studies including 764 transplanted patients were pooled in the meta-analysis. The pooled estimate of TRM was 2.1% (95% confidence interval [CI] 1.3%–3.4%). TRM was higher in older studies (p = 0.014) and in studies with a lower proportion of patients with relapsing-remitting MS (RRMS) (p = 0.028). A higher baseline Expanded Disability Status Scale (p = 0.013) was also significantly associated with a higher TRM. Pooled rate of progression was 17.1% at 2 years (95% CI 9.7%–24.5%) and 23.3% (95% CI 16.3%–31.8%) at 5 years. Lower 2-year progression rate was significantly associated with higher proportions of patients with RRMS (p = 0.004). The pooled proportion of NEDA patients at 2 years was 83% (range 70%–92%) and at 5 years was 67% (range 59%–70%).Conclusions: The emerging evidence on this therapeutic approach in MS indicates that the largest benefit/risk profile form this therapeutic approach can be obtained in patients with aggressive MS with a relapsing-remitting course and who have not yet accumulated a high level of disability.aHSCT=autologous hematopoietic stem cell transplantation; ARR=annualized relapse rate; ASTIMS=Autologous Hematopoietic Stem Cell Transplantation Trial in MS; CI=confidence interval; DMT=disease-modifying therapy; EBMT=European Society for Blood and Marrow Transplantation; EDSS=Expanded Disability Status Scale; IFN=interferon; MS=multiple sclerosis; NEDA=no evidence of disease activity; RRMS=relapsing-remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis; TRM=transplant-related mortality